Andrii Buvailo, PhD — Science and Tech Communicator, Writer, Editorial Strategist
Learning From Industry Leaders
The biotech industry is evolving fast—new technologies are redefining scientific workflows, and novel therapies are expanding beyond traditional small molecules. I connect directly with key opinion leaders to uncover insights on the latest innovations and opportunities in the space.
Check out some selected interviews below, and see the full lineup at BiopharmaTrend.com. Interested in an interview? Drop me a line!
-
How AbbVie Addresses Individuals Living with Migraine in Europe: Interview with Dr. Michael Seminerio
-
The Synergistic Potential of AI and Synthetic Biology: Interview with S&P Global’s Miriam Fernández
-
A Closer Look at Elsevier's AI Strategy in Drug Discovery: Interview with Mirit Eldor
-
A Company on the Cutting Edge of COVID-19 Vaccine Development. Interview With Peter H. Diamandis and Mei Mei Hu.
-
Shaping European Life Sciences with AI. Interview with Dr. Loubna Bouarfa, Founder and CEO at OKRA Technologies.
-
This Company Brings Quantum Tech Into Protein Design. Interview with Dr. Hans Melo, Co-founder, CEO of Menten AI,
-
A New Way To Work With Data In Life Sciences. Interview with Marilyn Matz, CEO and Co-founder at Paradigm4.
-
How COVID-19 Catalyzed AI-assisted Open Science Drug Discovery. Interview with Aaron Morris, Co-founder, and CEO at PostEra:
-
Hacking Metabolomics With AI To Improve Clinical Research. Interview with Dr. Elizabeth O'Day, CEO, and Founder of Olaris, Inc.
My Vision and Mission Statement
I am certain that we are entering a unique era in human history – the time when groundbreaking advances in life sciences, especially in gene editing, stem cells, “synbio”, and 3D bioprinting, will translate into a much wider scope of contexts, than just healthcare. Biology advances will revolutionize not only how we treat (and prevent) diseases, but also what we eat, how we deal with climate change, how we produce chemicals, and at the end of the day – who we will become as biological species. Yes, genetic engineering will one day start playing a major role in human development – from the very birth. We are not yet able to appreciate to what extent we will change biologically and physiologically over time – thanks to genetic engineering of germline cells, and the advent of high-tech, such as brain-computer interfaces, advanced prosthetic tech, artificial organs, longevity technologies, and so on.
This biotech revolution is largely enabled by an unprecedented advent of advanced technologies, such as Artificial Intelligence, big data manipulation, and exchange infrastructures (cloud, blockchain), robotization and remote labs, quantum computing, and so on. The coming decades will present a world of opportunities – and the biggest ones will be on the cross-section between biology and technology.
I am on a mission to identify and predict opportunities in the rapidly changing biotech environment, helping private, public, and government organizations to develop winning strategies for growth through innovation.